The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY) (#HOPE4KIDNEY)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05820087 |
Recruitment Status :
Recruiting
First Posted : April 19, 2023
Last Update Posted : March 25, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Renal Cancer Tumor, Solid Kidney Cancer Tumor Tumor, Benign | Device: HistoSonics Edison System | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 68 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | This trial is a prospective, multi-center, single-arm. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The HistoSonics Edison System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY US) |
Actual Study Start Date : | January 4, 2024 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2029 |
Arm | Intervention/treatment |
---|---|
Experimental: HistoSonics Edison System |
Device: HistoSonics Edison System
Non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.
Other Name: Histotripsy |
- Primary Effectiveness Endpoint - Primary technique efficacy defined as the percentage of targeted tumors that were successfully eliminated after a single histotripsy session as assessed by contrast enhanced MRI or CT at 90 days. [ Time Frame: 90 days Post Index Procedure ]Primary Effectiveness Endpoint
- Primary Safety Endpoint - Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the histotripsy procedure. [ Time Frame: 30 days Post Index Procedure ]Primary Safety Endpoint
- Secondary Effectiveness Endpoint- Technical success demonstrating complete coverage of the targeted tumor as determined post-index procedure (≤36 hours) by contrast enhanced MRI or CT in subjects whom treatment was initiated. [ Time Frame: Up to 36 hours Post Index Procedure ]Secondary Effectiveness Endpoint - Technical success defined as completion of histotripsy treatment according to protocol and demonstrating complete coverage of the targeted tumor as determined post-index procedure (≤36 hours) by contrast enhanced MRI or CT in subjects whom treatment was initiated.
- Secondary Safety Endpoint - Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 90 days after the histotripsy procedure. [ Time Frame: 90 days Post Index Procedure ]Secondary Safety Endpoint
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is ≥22 years of age.
- Subject has signed the Institutional Review Board (IRB) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
- Subject is diagnosed with only one (1) non-metastatic solid renal mass ≤3cm confirmed via CT or MRI ≤30 days prior to the index procedure date.
- Subject has had a biopsy to determine the type of tumor, ≥14 days prior to the index procedure.
- Subject can tolerate general anesthesia.
- Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2 at baseline screening.
-
Subject meets all the following functional criteria at ≤14 days prior to the planned index procedure date:
- White Blood Count (WBC) ≥3,000/mm3 (≥3 10*9/L)
- Absolute Neutrophil Count (ANC) ≥1,200/mm3 (≥1.2 10*9/L)
- Hemoglobin (Hgb) ≥9 g/dL
- Platelet count ≥100,000/mm3 (≥100 10*9/L)
- White Blood Count (WBC) ≤5 hpf via urinalysis
- Albumin ≤300 mg/g via urinalysis
- Subject has an eGFR (Glomerular filtration rate) ≥45mL/min, ≤14 days prior to the planned index procedure date.
- The tumor selected for histotripsy treatment must be ≤3cm in longest diameter.
- Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.
Exclusion Criteria:
- Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
- Subject is being actively treated in another pharmaceutical or device trial ≤30 days prior to planned index procedure date that may interfere with the primary endpoint(s).
- Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
- In the Investigator's opinion, the subject has co-morbid disease(s) or condition(s) that would cause undue risk and preclude safe use of the HistoSonics Edison System.
- Subject is on dialysis, being considered for dialysis or has acute renal failure.
- Subject has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or better from any adverse effects (except alopecia and neuropathy) related to previous therapy.
- Subject has an International normalized ratio (INR) >1.5 or uncorrectable coagulopathy, (e.g., known von Willebrand disease, hemophilia, or on anticoagulants), on the planned index procedure date.
- Subject is taking Aspirin (ASA) or NSAIDS ≤14 days prior to the planned index procedure date.
- Subject has a life expectancy less than one (< 1) year.
- In the investigator's opinion, histotripsy is not a treatment option for the subject.
- Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
- Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, radiation).
- Subject's targeted tumor is not treatable by the HistoSonics Edison System's working ranges (refer to User Guide).
- In the investigator's opinion, the anticipated risks of intervention outweigh the potential benefits of the intervention.
- Subject has bilateral kidney tumors or has a single functioning kidney.
-
Subject has a genetic predisposition to kidney cancer such as:
- Von Hippel Lindau (VHL)
- Hereditary Papillary Renal Carcinoma (HPRC)
- Birt-Hogg-Dubé Syndrome (BHD)
- Tuberous Sclerosis Complex (TSC)
- Hereditary Leiomyomata's Renal Cell Carcinoma (HLRCC)
- Reed's Syndrome
- Succinate Dehydrogenase B Deficiency (SDHB)
- BRCA 1 associated protein -1 (BAP1) Renal Cell Carcinoma
- MITF predisposed Renal Cell Carcinoma
- The targeted tumor is an angiomyolipoma.
- Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
- The targeted tumor is not clearly visible with ultrasound, MRI or CT.
- Targeted tumor with adequate margin overlaps the renal pelvis, main renal vessel, ureter, or other vital structure.
- The treatment of the tumor will not allow an adequate margin (as determined by the investigator).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05820087
Contact: Amber Dickson | 612-351-0361 | amber.dickson@histosonics.com | |
Contact: Zoe Secord | 612-351-0361 | zoe.secord@histosonics.com |
United States, California | |
University of Southern California | Recruiting |
Los Angeles, California, United States, 90089 | |
Contact: Ileana Aldana Ileana.Aldana@med.usc.edu | |
Principal Investigator: Monish Aron, MD | |
Sub-Investigator: Michael Katz, MD | |
United States, Connecticut | |
Yale School of Medicine | Recruiting |
New Haven, Connecticut, United States, 06510 | |
Contact: Kristin DeFrancesco kristin.defrancesco@yale.edu | |
Principal Investigator: David Madoff, MD | |
Sub-Investigator: Sandeep Arora, MD | |
United States, Florida | |
AdventHealth Celebration | Recruiting |
Celebration, Florida, United States, 34747 | |
Contact: Tracy Rivera, RN tracy.rivera@adventhealth.com | |
Principal Investigator: Michael McDonald, MD | |
United States, New York | |
Northwell Health | Recruiting |
Lake Success, New York, United States, 11042 | |
Contact: Sharon Choi schoi19@northwell.edu | |
Principal Investigator: Arun Rai, MD | |
Sub-Investigator: Manish Vira, MD | |
Sub-Investigator: Michael Schwartz, MD | |
NYU Langone Health | Recruiting |
New York, New York, United States, 10016 | |
Contact: Dayna Leis Dayna.Leis@nyulangone.org | |
Principal Investigator: William Huang, MD |
Responsible Party: | HistoSonics, Inc. |
ClinicalTrials.gov Identifier: | NCT05820087 |
Other Study ID Numbers: |
CSP2083 |
First Posted: | April 19, 2023 Key Record Dates |
Last Update Posted: | March 25, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Neoplasms Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Female Urogenital Diseases |
Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Kidney Diseases Urologic Diseases Male Urogenital Diseases |